A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series

Ir J Med Sci. 2012 Jun;181(2):211-4. doi: 10.1007/s11845-011-0780-7. Epub 2011 Nov 3.


Background: The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.

Aim: The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.

Method: We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.

Result: The median progression-free survival was 17 months (range 3-48+ months), and overall survival 31 months (range 12-53+ months) with no toxicity related deaths.

Conclusion: FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.

MeSH terms

  • Adenoma, Islet Cell
  • Adult
  • Aged
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Antimetabolites, Antineoplastic / adverse effects
  • Carcinoid Tumor / drug therapy*
  • Carcinoid Tumor / secondary
  • Disease-Free Survival
  • Drug Therapy, Combination
  • Female
  • Fluorouracil / administration & dosage*
  • Fluorouracil / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy*
  • Neuroendocrine Tumors / secondary
  • Streptozocin / administration & dosage*
  • Streptozocin / adverse effects


  • Antibiotics, Antineoplastic
  • Antimetabolites, Antineoplastic
  • Streptozocin
  • Fluorouracil